Reneo Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Onkure Therapeutics

11/05/2023 14:27

* Reneo Pharmaceuticals Inc  RPHM.OQ  reported a quarterly
adjusted loss of 60 cents​​ per share for the quarter ended in
March. The mean expectation of five analysts for the quarter was
for a loss of 60 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Reneo Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 60 cents​.
    * The mean earnings estimate of analysts had fallen by
about 5.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Reneo Pharmaceuticals Inc shares had risen by 33.4% this
quarter and gained 242.5% so far this year.
    * The company reported a quarterly loss of $15.11 million.
    * Wall Street's median 12-month price target for Reneo
Pharmaceuticals Inc is $26.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 01:27 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.60          -0.60          Met
 Dec. 31 2022      -0.60          -0.56          Beat
 Sep. 30 2022      -0.57          -0.53          Beat
 Jun. 30 2022      -0.58          -0.50          Beat